11826096(11826096) - 在研适应症：乙型肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Compound 11826096、Hepatitis B disease(Collaborations Pharmaceuticals)

+ [1]

靶点-

作用机制-

治疗领域

感染消化系统疾病

在研适应症

乙型肝炎

非在研适应症-

原研机构

Collaborations Pharmaceuticals, Inc.初创企业

在研机构

Collaborations Pharmaceuticals, Inc.初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C29H55Cl4N11

InChIKeyZDXNNKALUUQBBT-UHFFFAOYSA-J

CAS号-

关联

100 项与 11826096 相关的临床结果

登录后查看更多信息

100 项与 11826096 相关的转化医学

登录后查看更多信息

100 项与 11826096 相关的专利（医药）

登录后查看更多信息

1

项与 11826096 相关的文献（医药）

2023-09-14·Journal of Medicinal Chemistry1区 · 医学

Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus

1区 · 医学

Article

作者: Makarov, Vadim ; Bradley, Daniel P. ; Monakhova, Natalia ; Lane, Thomas R. ; Ekins, Sean ; Jones, Thane ; Li, Qilan ; Tavis, John E. ; Riabova, Olga

Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates by reverse transcription. It chronically infects >296 million people worldwide, including ∼850,000 in the USA, and kills 820,000 annually worldwide. Current nucleos(t)ide analogue (NA) or pegylated interferon α therapies do not eradicate the virus and would benefit from a complementary antiviral drug. We performed a preliminary screen of 28 dispirotripiperazines against HBV, identifying 9 hits with EC₅₀ of 0.7-25 μM. Compound 11826096 displays the most potent activity and represents a promising lead for future optimization. While the mechanism of action is unknown, preliminary assays limit possible targets to activities involved in RNA accumulation, translation, capsid assembly, and/or capsid stability. In addition, we built machine learning models to determine if they were able to predict the activity of this series of compounds. The novelty of these molecules indicated they were outside of the applicability domain of these models.

100 项与 11826096 相关的药物交易

登录后查看更多信息